Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial.
de Tute RM, Cook G, Cairns DA, Brown JM, Cavenagh J, Ashcroft AJ, Snowden JA, Yong K, Tholouli E, Jenner M, Hockaday A, Drayson MT, Morris TCM, Rawstron AC, Owen RG. de Tute RM, et al. Among authors: rawstron ac. Bone Marrow Transplant. 2024 Mar;59(3):431-434. doi: 10.1038/s41409-023-02164-4. Epub 2024 Jan 9. Bone Marrow Transplant. 2024. PMID: 38195983 Free article. No abstract available.
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.
de Tute RM, Rawstron AC, Gregory WM, Child JA, Davies FE, Bell SE, Cook G, Szubert AJ, Drayson MT, Jackson GH, Morgan GJ, Owen RG. de Tute RM, et al. Among authors: rawstron ac. Haematologica. 2016 Feb;101(2):e69-71. doi: 10.3324/haematol.2015.128215. Epub 2015 Oct 15. Haematologica. 2016. PMID: 26471484 Free PMC article. Clinical Trial. No abstract available.
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, Jones JR, Hockaday A, Henderson R, Cook G, Drayson MT, Jenner MW, Kaiser MF, Gregory WM, Morgan GJ, Jackson GH, Owen RG. de Tute RM, et al. J Clin Oncol. 2022 Sep 1;40(25):2889-2900. doi: 10.1200/JCO.21.02228. Epub 2022 Apr 4. J Clin Oncol. 2022. PMID: 35377708
Minimal residual disease monitoring in multiple myeloma.
Davies FE, Rawstron AC, Owen RG, Morgan GJ. Davies FE, et al. Among authors: rawstron ac. Best Pract Res Clin Haematol. 2002 Mar;15(1):197-222. doi: 10.1053/beha.2002.0192. Best Pract Res Clin Haematol. 2002. PMID: 11987924 Review.
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Cohen OC, Counsell N, Rabin N, Popat R, Owen RG, Popova B, Schofield O, Clifton-Hadley L, Lyons-Lewis J, Rawstron A, Spence C, de Tute RM, Hughes D, Moore S, Smith P, Yong KL. Cohen OC, et al. Br J Haematol. 2019 Jun;185(5):948-951. doi: 10.1111/bjh.15649. Epub 2018 Nov 20. Br J Haematol. 2019. PMID: 30460696 Free article. No abstract available.
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, Paneesha S, Fox CP, Eyre TA, Forconi F, Elmusharaf N, Kennedy B, Gribben J, Pemberton N, Sheehy O, Preston G, Schuh A, Walewska R, Duley L, Howard D, Hockaday A, Jackson S, Greatorex N, Girvan S, Bell S, Brown JM, Webster N, Dalal S, de Tute R, Rawstron A, Patten PEM, Hillmen P; National Cancer Research Institute Chronic Lymphocytic Leukemia Subgroup. Munir T, et al. N Engl J Med. 2024 Jan 25;390(4):326-337. doi: 10.1056/NEJMoa2310063. Epub 2023 Dec 10. N Engl J Med. 2024. PMID: 38078508 Clinical Trial.
165 results